HighTower Advisors LLC boosted its position in shares of Danaher Corporation (NYSE:DHR – Free Report) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 419,053 shares of the conglomerate’s stock after purchasing an additional 10,404 shares during the quarter. HighTower Advisors LLC’s holdings in Danaher were worth $95,930,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Elevated Capital Advisors LLC acquired a new position in Danaher during the fourth quarter valued at approximately $26,000. JPL Wealth Management LLC acquired a new position in Danaher during the third quarter valued at approximately $25,000. WFA of San Diego LLC acquired a new position in Danaher during the second quarter valued at approximately $26,000. ANTIPODES PARTNERS Ltd acquired a new position in Danaher during the third quarter valued at approximately $27,000. Finally, Financial Life Planners bought a new position in Danaher in the third quarter valued at approximately $32,000. Institutional investors and hedge funds own 79.05% of the company’s stock.
Danaher Stock Performance
Shares of DHR stock opened at $166.97 on Wednesday. The company’s fifty day simple moving average is $184.97 and its 200-day simple moving average is $209.60. The company has a quick ratio of 1.52, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a market cap of $118.18 billion, a PE ratio of 32.30, a P/E/G ratio of 2.19 and a beta of 0.81. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.
Danaher Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s payout ratio is currently 30.95%.
Analyst Upgrades and Downgrades
DHR has been the topic of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $245.00 price target on shares of Danaher in a research note on Tuesday, April 21st. JPMorgan Chase & Co. cut their price target on shares of Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. Robert W. Baird cut their price target on shares of Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Guggenheim cut their price target on shares of Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, Argus cut their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Nineteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $238.65.
Read Our Latest Stock Report on DHR
Insider Activity at Danaher
In other news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the sale, the executive vice president owned 5,099 shares of the company’s stock, valued at $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.80% of the stock is currently owned by corporate insiders.
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
See Also
- Five stocks we like better than Danaher
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
